• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $APUS

    Apimeds Pharmaceuticals US Inc.

    Subscribe to $APUS
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2025

    Exchange: AMEX

    Recent Analyst Ratings for Apimeds Pharmaceuticals US Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Apimeds Pharmaceuticals US Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CMO Kim Christopher bought $50,359 worth of shares (27,500 units at $1.83) (SEC Form 4)

      4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

      5/15/25 6:48:30 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Koo Jakap bought $56,715 worth of shares (28,500 units at $1.99), increasing direct ownership by 5% to 643,885 units (SEC Form 4)

      4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

      5/14/25 5:58:18 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Inscobee Inc. bought $2,000,000 worth of shares (500,000 units at $4.00) and converted options into 297,133 shares, increasing direct ownership by 37% to 2,028,657 units (SEC Form 4)

      4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

      5/14/25 5:52:52 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apimeds Pharmaceuticals US Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CMO Kim Christopher bought $50,359 worth of shares (27,500 units at $1.83) (SEC Form 4)

      4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

      5/15/25 6:48:30 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Koo Jakap bought $56,715 worth of shares (28,500 units at $1.99), increasing direct ownership by 5% to 643,885 units (SEC Form 4)

      4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

      5/14/25 5:58:18 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Inscobee Inc. bought $2,000,000 worth of shares (500,000 units at $4.00) and converted options into 297,133 shares, increasing direct ownership by 37% to 2,028,657 units (SEC Form 4)

      4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

      5/14/25 5:52:52 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: New insider Inscobee Inc. claimed ownership of 5,619,232 shares (SEC Form 3)

      3/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

      5/14/25 5:32:08 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apimeds Pharmaceuticals US Inc. SEC Filings

    See more
    • SEC Form NT 10-Q filed by Apimeds Pharmaceuticals US Inc.

      NT 10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

      5/15/25 4:22:35 PM ET
      $APUS
      Biotechnology: Pharmaceutical Preparations
      Health Care